



#### HISTIOCYTOSES/NEOPLASMS OF THE MACROPHAGE-DENDRITIC CELL LINEAGE





### LANGERHANS CELL HISTIOCYTOSIS


Definition


- proliferation of dendritic cells with the same immunophenotype as specialized dendritic cells - "epidermal Langerhans cells" - found in the skin and mucosa
- may affect any anatomic site
  - single or multifocal (confined to an organ system, particularly bone, especially in children)
  - disseminated disease can include wide range of anatomic sites including skin (40%)
- may be associated with diabetes insipidus

### LANGERHANS CELL HISTIOCYTOSIS

#### Morphology

- large, oval cells with grooved nuclei and dispersed chromatin
- do not display dendritic processes
- background of (often abundant) small lymphocytes, eosinophils macrophages, multinucleated giant cells > neutrophils, plasma cells
- lesional cells may be sparse in later lesions
- shows sinusoidal pattern in LN







### LANGERHANS CELL HISTIOCYTOSIS

#### Immunophenotype

- "Langerhans cell" markers
  - S100+ (nuclear and cytoplasmic)
  - CD1a+
  - langerin (CD207)+
- "macrophage" markers
  - CD68 -/+, CD163 -
  - lysozyme weak to negative (but admixed macrophages will be strongly positive)






#### LANGERHANS CELL HISTIOCYTOSIS Pulmonary LCH • >90% in young or ex-smokers peak incidence between 20 and 40 years • granulomas form around small airways and can be • destructive/cause tissue remodeling composed of Langerhans cells with the same • immunophenotype as LCH at other sites debate: reactive, clonal or neoplastic? ٠ unpredictable clinical course ٠ • may resolve with smoking cessation • may require therapeutic intervention recurrent genetic abnormalities • • BRAF V600E (30-50%) • MAP2K1 mutations (mutually exclusive with BRAF mutations)


Vassallo R et al. Thorax. 2017;72:937-945

# LANGERHANS CELL HISTIOCYTOSIS Differential diagnosis Langerhans cell hist

- reactive Langerhans cell collections
- indeterminate dendritic cell tumor
- Langerhans cell sarcoma




reactive Langerhans cells have dendritic processes (best seen on CD1a IHC)



### INDETERMINATE DENDRITIC CELL TUMOR

- extraordinarily rare
- involves dermis; may extend to subcutis
- multiple generalized papules, nodules or plaques
- cells resemble Langerhans cells morphologically
- S100+, CD1a+; langerin-negative
- no Birbeck granules on EM
- may have BRAF V600E mutation
- few cases with ETV3-NCOA2 translocation





Clinical image courtesy of Dr. Mackenzie Asel

### ERDHEIM-CHESTER DISEASE

#### Clinical features

• adults, M>F

no LN involvement, in contrast to LCH




- bilateral, symmetric osteosclerotic lesions (95%)
   may also involve extraskeletal tissues
  - restrictive pericarditis
  - perinephric fibrosis
  - yellow plaques (commonly eyelids/periorbital): xanthelasma
  - central diabetes insipidus
- variable clinical outcomes: indolent to lifethreatening
- high prevalence of concomitant myeloid neoplasms → bmbx recommended, esp in setting of unexplained CBC abnormalities
- diagnosis requires clinicopathologic and radiologic correlation

Goyal G et al. *Blood*. 2020; 135(22):1929-45. Chasset F et al. *Am J Acad Dermatol*. 2016;74:513-20.

Organ system and clinical findings	NIH patients,* n (%)		eyssier-Belot et al† (%)	Haroche et al‡ (%)	
Bone	57 (95)		NR	96	
Kidney	39 (65)		27	68	
Periaortic encasement	37 (62)		NR	66	
Hypogonadism	36 (60)		NR	NR	
Lung	31 (52)		14	43	
Bone pain	28 (47)		47	40	
Maxilla and mandible§	24 (47)		NR	NR	
Diabetes insipidus	28 (47)		29	25	
CNS disease infiltration	23 (38)		17	51	
Retro-orbital area $\pm$ exophthalmos	15 (27)		29	25	
Heart (pseudotumor in RA)	22 (37)		NR	19	
Xanthelasma	20 (33)		19	28	
Skin	15 (25)		10	NR	
Pericardial disease	5 (8)		7	42	

Diamond EL et al. *Blood*. 2014;124(4):483-492. Estrada-Veras JI. *Blood Adv*. 2017;1(6): 357-66.




### ERDHEIM-CHESTER DISEASE


#### Morphology & immunophenotype

- Classic:
  - sheets of foamy macrophages/ xanthogranulomatous infiltrates
  - multinucleated Touton cells
  - fibrosis
  - mixed inflammatory cells: lymphocytes/plasma cells > neutrophils
- Atypical:
  - florid lymphohistiocytic infiltrates
  - fibrosis with scattered foamy histiocytes and rare/absent Touton giant cells
- PU.1+, CD68+, CD163+, lysozyme+, fascin+
- CD1a-negative, Langerin-negative
- 20-30% weak/focal S100 expression

may be difficult/impossible to distinguish from reactive xanthomatous macrophages in the setting of chronic inflammatory conditions based solely on histologic/immunophenotypic features

Chasset F et al. Am J Acad Dermatol. 2016;74:513-20.






### JUVENILE XANTHOGRANULOMA

#### Most cases:

- solitary or several red-yellow papules/nodules
- resembles dermatofibroma or Spitz nevus
- well-circumscribed nodule
- epidermal collarette
- histiocytes/foamy cells, Touton giant cells, lymphocytes, eosinophils
- Positive for CD68, CD163; negative CD1a, langerin
- may contain S100+ cells with emperipolesis
- most skin-only cases do not have underlying mutations, although may be associated with NF1
- benign outcome: may resolve spontaneously

#### Disseminated/systemic form (~5%)

- typically infant to 10 years old; may occur in adults
- can involve mucosal surfaces, CNS, dura, pituitary stalk, eye, liver, lung, LN and BM; potential for morbidity and mortality
  - challenging area for classification (await 2022 WHO) recurrent BRAFV600E, NTRK1 fusions and mutations in MAP2K1 and CSF1R
  - "consider as ECD all extracutaneous or disseminated JXG with gain-of-function mutation of BRAF, NRAS, KRAS, or MAP2K1" (Emile JF et al. Blood. 2016;127(22):2672-2681.)
  - BRAFV600E "positive cases should be strongly favored to be in ECD family" (Goyal G et al. Blood. 2020; 135(22):1929-45.)




### ALK-RELATED HISTIOCYTOSIS

XUSCAP Modern Pathology (2019) 32:598–608 https://doi.org/10.1038/s41379-018-0168-6 ALK-positive histiocytosis: an expanded clinicopathologic spectrum and frequent presence of KIF5B-ALK fusion Kenneth Tou En Chango<sup>1,2</sup> · Amos Zhi En Tay<sup>1</sup> · Chik Hong Kuick<sup>1</sup> · Huivi Chen<sup>1</sup> · Elizabeth Algar<sup>3,4</sup> Nadine Taubenheim<sup>3</sup> Janine Campbell<sup>5</sup> · Francoise Mechinaud<sup>6</sup> · Martin Campbell<sup>6</sup> · Leanne Super<sup>6</sup> · Chavit Chantranuwat<sup>7</sup> · S. T. Yuen<sup>8</sup> · John K. C. Chan<sup>9</sup> · Chung W. Chow<sup>10,11</sup> 10 cases • 6 disseminated (infant to toddler at presentation; 5 of 6 with eventual disease resolution) • 4 localized (nasal skin, foot, breast, and intracranial cavernous sinus - surgical resection or crizotinib) • large cells with irregularly folded nuclei, fine chromatin, and abundant eosinophilic cytoplasm +/- emperipolesis

typically not xanthomatous

ARTICLE

- positive for ALK1, CD68, CD163; +/- S100; negative for CD1a, Langerin
- features resembling JXG (foamy histiocytes, Touton giant cells) may arise over time
- KIF5B-ALK fusion (n=5), COL1A2-ALK (n=1); no correlation with anatomic distribution





- authors propose that ALK-positive histiocytosis likely represents a distinct clinicopathologic entity
  - should the few prior cases of JXG and ECD with ALK fusions be classified as ALK-positive (ALK-related) histiocytosis?
  - await 2022 WHO classification
- recommend performing ALK1 IHC on all atypical histiocytic proliferations  $\rightarrow$  may provide a therapeutic option (regardless of histologic classification)

### ROSAI-DORFMAN DISEASE

#### Clinical & morphologic features

- painless, massive lymphadenopathy
- fever, night sweats, weight loss, fatigue
- elevated ESR, polyclonal hypergammaglobulinemia
- ~40% of cases with extranodal involvement
- large histiocytic cells with emperipolesis
- lymphocytes, plasma cells, neutrophils, non-RD histiocytes
- eosinophils typically not seen
- may see increased IgG4+plasma cells → systemic evaluation for associated IgG4-related disease recommended if IgG:IgG4 >40%
- other histiocytoses may show occasional emperipolesis (JXG; LCH/sarcoma; HS)
- positive for CD68, CD163, PU.1, fascin, lysozyme, factor XIIIa
- positive for \$100
- positive for cyclin D1 and pERK (active MAPK–ERK pathway)
- negative for CD1a and langerin (CD207)






### HISTIOCYTIC SARCOMA

Clinical features


- rare, aggressive, adults
- malignant proliferation of cells with features of tissue histiocytes
- often extranodal tissues, including skin
- may arise in patients with mediastinal germ cell tumors (typically malignant teratoma)
- may arise in patients with other hematopoietic neoplasm, especially lymphoma or acute lymphoblastic leukemia





### HISTIOCYTIC SARCOMA

#### Morphology

- sheets of large cells with pleomorphic nuclei and abundant eosinophilic cytoplasm
- typically non-cohesive but may have sinusoidal distribution in LN, spleen, liver
- frequent mitoses
- variable inflammatory background (may obscure neoplastic cells, particularly in CNS)









### INTERDIGITATING DENDRITIC CELL SARCOMA

#### Clinical features & morphology

- interdigitating dendritic cell: antigen-processing cells in T-cell rich zones •
- rare •
- commonly presents as asymptomatic mass •
- LN > extranodal sites ٠
- prognosis varies; 2-year OS for localized (68.5%) vs. systemic (15.8%) disease may be past history of hematologic or solid tumor
- malignancy
- storiform architecture •
- classically spares follicles
- spindled and ovoid cells
- vesicular chromatin, indistinct cell borders, eosinophilic cytoplasm
- admixed small lymphocytes •
- low mitotic rate
- typically frank necrosis is not seen

Ninkovic S et al. Pathology. 2017 Oct;49(6):643-646.





### INTERDIGITATING DENDRITIC CELL SARCOMA

#### Immunophenotype


- CD45RO+
- S100+
- CD45+/-
- CD68+/-, lysozyme+/-
- PU.1+ in our lab
- negative for CD21, CD23, CD35 (+ in follicular dendritic cell sarcoma, which is a morphologic mimic)
- negative for CD1a and langerin
- BRAF V600E mutations have been described

#### Spindle Cell Melanoma and Interdigitating Dendritic Cell Sarcoma

#### Do They Represent the Same Process?

Anne M. Stowman, MD, Stacey E. Mills, MD, and Mark R. Wick, MD Am J Surg Pathol • Volume 40, Number 9, September 2016

Fachetti F et al. Virchows Arch 2017;471:467-489.



CS Patient	SOX-10	MiT
	Strong nuclear	Negat


ID

SOX10 - SOX family of transcription factors; neural crest and peripheral nervous system development; melanoma, MPNST

IDCS negative for SOX10 in our lab – extreme caution needed before rendering dx of IDCS if SOX10+, despite reports in literature. Perform full melanoma work-up if SOX10+!

### LANGERHANS CELL SARCOMA

- extremely rare
- same immunophenotype as LCH (S100+, CD1a+, langerin+) but very high Ki67
- does not arise from LCH
- distinguished from LCH by:
  - morphology marked nuclear pleomorphism, numerous mitoses (>50 per 10 high-powered fields)
  - clinical course aggressive, rapid
- cells may show "grooves" as in LCH
- eosinophil infiltrate not a consistent feature
- single or multiple anatomic sites
  - typically extranodal (skin, bone, soft tissue)
- BRAF V600E mutation has been described



Ferringer T et al. Am J Dermatopathol. 2006. 28:36-39.

	Progenitor	Progenitor Key IHC 5th ed. WHO Histiocytic/Dendritic Cell			Histiocyte Society		
		Neoplasms Chapter (pre				Classification	
Langerhans cell histiocytosis	Hematopoietic	S100, CD1a, Langerin	Yes				L group
Indeterminate dendritic cell tumor	Hematopoietic	S100, CD1a		Yes			L group
Erdheim-Chester disease	Hematopoietic	"Macrophage" markers			Yes		L group
Juvenile xanthogranuloma	Hematopoietic	"Macrophage" markers			Yes (modified heading)		L group/C group
ALK-related histiocytosis	Hematopoietic	"Macrophage" markers; ALK1			Yes (new)		L group
Rosai-Dorfman disease	Hematopoietic	"Macrophage" markers; S100			Yes (new)		R group/C group
Histiocytic sarcoma	Hematopoietic	"Macrophage" markers			Yes		M group
Interdigitating dendritic cell sarcoma	Hematopoietic	S100; variable CD68, lysozyme		Yes			M group
Langerhans cell sarcoma	Hematopoietic	S100, CD1a, Langerin	Yes				M group
Blastic plasmacytoid dendritic cell neoplasm	Hematopoietic	Gabe Griffin will discuss				Yes (new)	N/A
Follicular dendritic cell sarcoma Inflammatory EBV+ FDCS	Mesenchymal	CD21, CD23, CD35 EBV	No (differe	No (different chapter)		N/A	
Fibroblastic reticular cell tumor	Mesenchymal	SMA, desmin, cytokeratin (dendritic pattern), CD68	No (different chapter)		N/A		

### TAKE-AWAYS

- variable classification systems
  - WHO (current 4<sup>th</sup> revised edition; some modifications in forthcoming 5<sup>th</sup> edition)
  - Histiocyte Society
- S100+
  - Langerhans cell histiocytosis, Langerhans cell sarcoma, indeterminate dendritic cell tumor, interdigitating dendritic cell sarcoma, Rosai-Dorfman disease, -/+ histiocytic sarcoma, -/+ Erdheim-Chester, +/- ALK-related histiocytosis
  - melanoma is much more common than these diagnoses always consider it (esp. spindle-cell melanoma) in your work-up
- BRAF<sup>V600E</sup> and ALK1 IHC and genetic analysis (particularly for RAS-MAPK or PI3K signaling pathway alternations) recommended
  - may provide evidence of clonality in cases with morphologic overlap with reactive conditions
    - cyclin D1 and pERK IHC expression can imply activation of the RAS-MAPK signaling pathway
  - may reveal therapeutic targets
- · histiocytic and dendritic cell neoplasms may arise following immature or mature hematopoietic neoplasms
  - consider them in the differential diagnosis of spindled or large-cell neoplasms arising in this setting



## IMMUNOHISTOCHEMISTRY (APPENDIX)

Antigen	Main reactivity in normal cells	Diagnostic usefulness, pearls, and pitfalls		
BRAF V600E	None	High sensitivity and specificity for cells carrying this mutation	Macrophage Markers	Also reactivity in
		(clone VE1). The mutation itself is not specific for any disease and may occur also in epithelial cancers and melanoma		Depends on clone (PG-M1 more specific than KP-1)
CD1a	LC, dermal DC (subset), IDC	Required for diagnosis of LCH/LCS and IND-DCT	CD68: glycoprotein present in	Myeloid cells
	(subset), IDC (subset)	Positivity excludes IDCS	lysosome, phagosomes, and	Mast cells
CD4	All DC and H/M	Limited usefulness, due to wide expression		Lymphocytes
		Generally diffuse cytoplasmic stain, in contrast to T cells where it is membranous	(cytoplasmic; may be granular)	Some epithelial cells/tumors Schwannoma Granular cell tumor
CD14	H/M	H/M-derived tumors (less frequently than in monocytic leukemias)		Melanoma (subset)
CD68	H/M	Most H/M-derived tumors show diffuse granular cytoplasmic re-	CD163: plasma membrane	AML with monocytic differentiation
PDC	activity; positivity in DC neoplasms more variable; BPDCN often negative	glycoprotein	Giant cell tenosynovial tumor	
		Clone PGM1 should be preferred to others since it does not stain myeloid cells	(membranous/cytoplasmic)	Littoral cell angioma
CD123 PDC and activated		High sensitivity and specificity for BPDCN	Lysozyme: glycoside hydrolase	Granulocytes/myeloid malignancies
	H/M	Can be expressed in LCH and in H/M-derived tumors		Some epithelial cells/epithelial neoplasms
CD163	H/M	High sensitivity and specificity for H/M-derived tumors	(cytoplasmic; may be granular)	Granuloma annulare
CD207/langerin	LC, IDC (subset)	Defining LCH/LCS. Excludes IDCS		Granulonia annulare
CD303/BDCA2	PDC	High specificity for BPDCN	PU.1: transcription factor	Granulocytes
Factor XIIIa	H/M	H/M-derived tumors	(nuclear)	B-lineage
HLA-DR	H/M, DC	Paranuclear dot expression in LCH/LCS, IND-DCT, and IDCS. Useful to distinguish tumoral from reactive LC proliferations (see text)	(nucleary	5 mease
Lysozyme	H/M	H/M-derived tumors		
S100 protein	LC, IDC, activated	Required for diagnosis of LCH/LCS, IND-DCT, IDCS		
H/M	Tumoral H/M can express \$100 in variable number of cells			
		Required for diagnosis of RDD		
TCL1	PDC	High sensitivity and specificity for BPDCN		

Disease	ECD	JXG/AXG	ALK <sup>+</sup> histiocytosis	RDD	LCH
Immunophenotype					
CD68 (cytoplasmic)	++	++	++	++	+ (paranuclear cytoplasmic dot)
CD163 (surface)	++	++	++	++	_
CD14 (surface)	++	++	++	++	_
CD1a (surface)	_	-	-	-	++
CD207 (Langerin) (cytoplasmic)	_	-	-	_	++
S100 (cytoplasmic/ nuclear)	-/+ (light)	—/+ (light)	-/++ (in some cases dark staining)	+	+
Factor XIIIa (cytoplasmic)	+	+	+	+	-
Fascin (cytoplasmic)	+	+	+	+	-
CD45 (light surface)	+	+	+	+	+
BRAF VE1 (cytoplasmic)	++*	<ul> <li>(Positive cases should be strongly favored to be in ECD family)</li> </ul>	_	<ul> <li>(Rare case reports</li> <li>++)</li> </ul>	++*
ALK (cytoplasmic)	++*	++*	++*	_	-
NTRK1(cytoplasmic)	++*	++*	-	_	-